The Utility of Clinical or Genetic Data to Predict Treatment Response in ADHD

  • Release date: October 1, 2023
  • Expiration date: October 2, 2024
  • Estimated time to complete activity: 1.0 hour
  • Please contact MER ( for any questions regarding this activity.
  • MER Privacy Policy
  • This activity is jointly provided by Medical Education Resources and MedLearning Inc.
  • This activity is supported by an educational grant from Supernus.
Please scroll down and click on "Presentation" to view the video


Accreditation/CME Information

Target Audience

This activity has been designed to meet the educational needs of MD/DO, NP/PA, and nurses involved in the care of patients with Attention-Deficit/Hyperactivity Disorder (ADHD).

Statement of Need/Program Overview

According to our needs assessments, PCPs have little training about how to diagnose and treat ADHD.   PCPs (physicians, nurse practitioners and physician assistants) know little about the comparative effectiveness and cost-effectiveness of the diagnostic and treatment options for these disorders.  Despite this lack of knowledge, PCPs are usually the first clinicians to be in contact with adults with ADHD (Mitchell, 2009, Montano, 2004). 

Adler et al. (2009) found that 48% of PCPs did not feel competent to diagnose adult ADHD; 44% incorrectly believed that no structured diagnostic criteria are available for the disorder. 75% held the mistake belief that existing adult ADHD diagnostic tools were of poor or fair quality. Mean scores on 12 evidence-based questions were lower for primary care physicians than for psychiatrists as was awareness of the prevalence of ADHD in adults.   

Educational Objectives

After completing this activity, the participant should be better able to:

  • Review precision models in psychiatry
  • Evaluate pharmacogenetic targets for drug response in ADHD
  • Assess the utility of clinical and genetic data to predict treatment response in ADHD


Stephen V. Faraone, PhD
Distinguished Professor and Vice Chair for Research
Department of Psychiatry, Norton College of Medicine, SUNY Upstate Medical University
Syracuse, New York

Program Agenda

45-minute presentation

15-minute evaluation

Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and MedLearning Inc. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Credit

Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Disclosure of Relevant Financial Relationships

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity: 

Name of Faculty

Reported Financial Relationship

Stephen V. Faraone, PhD

Grants/Research Support: Otsuka, Shire/Takeda, Supernus

Consulting Fees (eg. Ad Boards: Aardvark, Aardwolf, Atentiv, Axsome, Ironshore, Corium, Genomind, Sky Therapeutics, Medice, Noven, Rhodes, Supernus, Tris, Vallon

Speakers’ Bureau: Lecture Honoraria: Supernus, Sandoz, Otsuka, Tris

Ownership Interest/Shareholder: Aardvark, Aardwolf, Akili, Ironshore, Sky Therapeutics, Genomind

Royalty/Patent Holder: Elsevier, Guilford Press, Oxford University Press, US Patent (US20130217707 A1)

The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity: 

Name of Content Manager

Reported Financial Relationship

Cassandra Matthews, PharmD

No relevant financial relationships to disclose

Planners at Medical Education Resources

No relevant financial relationships to disclose

Method of Participation

There are no fees for participating in and receiving credit for this activity. During the period October 2023 through October 2024, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form. Statements of credit will be issued online at the time of completion.




The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, MedLearning Inc., and/or Supernus. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management. 

Fee Information

There is no fee for this educational activity. 

MER Privacy Policy

Medical Education Resources and MedLearning Inc. maintain high standards for the protection of privacy over the Internet. The purpose of this statement is to explain what information we obtain, how it is used, and how visitors can restrict its use or disclosure.

The only information MER obtains is information supplied voluntarily by the visitor.

We do not sell or disclose individually identifiable information obtained online unless it is required by law or disclosure is necessary to protect the safety of customers, employees, or property.

We use the information to issue a certificate of completion of the activity. If we use a third-party company issue certificates of completion, we will give the information to that company for that purpose only.

For each activity that you take, you must complete an evaluation questionnaire. That questionnaire may ask if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.

We may use the information to invite you to participate in other activities that we may offer.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, MER will not share the names or contact information of learners with any ineligible company or its agents without the explicit consent of the individual learner.

Medical Education Resources is committed to safeguarding customer privacy, and we require our employees to protect the privacy of information about our customers. Should you wish to delete your information from our files or discuss our privacy policy, please contact us.